Mucosolvan Inhalacje (Ambroxol Hydrochloride)

Ambroxol stimulates serous cells in the airway lining, increasing the secretion of thin, watery fluid. This action lowers mucus viscosity and enhances ciliary movement, allowing mucus to be transported more efficiently toward the throat for expectoration. The drug may also boost surfactant production and modulate inflammatory pathways, further aiding airway clearance.

The specific dose and frequency of Mucosolvan Inhalacje are determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and overall clinical condition. The prescriber will select the appropriate inhalation volume and schedule to achieve optimal mucus clearance while monitoring for tolerance.

Safety data for ambroxol inhalation in pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will assess individual circumstances before recommending therapy during pregnancy or while breastfeeding.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and assistance with import documentation.

Mucosolvan (ambroxol) is a direct‑acting mucolytic that increases serous secretion, whereas agents such as N‑acetylcysteine act primarily by breaking disulfide bonds in mucus proteins. Ambroxol often provides a faster onset of mucus thinning and may have additional anti‑inflammatory effects, but the choice of agent depends on patient tolerance, comorbidities, and clinician preference.

Store the inhalation solution at room temperature, preferably below 25 °C, in its original container. Protect it from direct sunlight, moisture, and extreme temperature fluctuations. Ensure the vial or ampoule is tightly sealed when not in use and keep it out of reach of children.

The product is delivered via a nebulizer or a compatible inhalation device. The prescribed volume of solution is placed in the nebulizer cup, and the patient inhales the aerosolized mist for the duration recommended by the prescriber, typically several minutes, until the dose is fully administered.

Serious adverse reactions, although rare, include severe allergic responses such as rash, urticaria, angioedema, and anaphylactic shock. Life‑threatening bronchospasm or respiratory distress may also occur, particularly in individuals with underlying airway hyperreactivity. Prompt medical attention is required if any of these symptoms develop.

Mucosolvan Inhalacje is contraindicated in patients with a known hypersensitivity to ambroxol or any component of the formulation. It should also be avoided in individuals who have experienced severe bronchospasm or allergic reactions to mucolytic agents. Clinicians should assess each patient’s medical history before initiating therapy.